Abstract. Although gemcitabine (GEM) is widely used in the treatment of pancreatic cancers, the molecular mechanisms that underlie its anti-tumor effects are not fully understood. To clarify the anti-tumor mechanism(s) of GEM, we studied a human pancreatic cancer cell line, YPK-1, that showed a 50% inhibitory concentration (IC50) of GEM of 6.3x10
Introduction
Pancreatic cancer is a devastating disease with a short survival after diagnosis because of its high metastatic potential (1, 2) . The development of anti-cancer drugs is necessary for the effective treatment of pancreatic cancer. Gemcitabine (GEM) is a novel nucleoside analogue that has significant anti-tumor activity against various solid tumors, including pancreatic cancer, head and neck cancer, and non-small cell lung cancer (3) (4) (5) , and it is more effective than fluorouracil in reducing symptoms in pancreatic cancer patients. Because GEM confers a small survival benefit to patients with pancreatic cancer, it is used as a first-line therapy for patients with advanced pancreatic cancer (6) .
GEM does not always induce a complete response in all types of tumors; however, many studies have shown its clinical efficacy in the treatment of pancreatic cancer (7, 8) . GEM is phosphorylated and metabolized and then incorporated into cellular DNA. As a result, it causes masked chain termination (9, 10) . GEM sensitivity of cells is known to be affected by pathways that involve ribonucleotide reductase E2F1 and Bcl-2 (11) (12) (13) . However, these pathways cannot account for all of the biological effects of GEM on cells, and therefore other pathways should be investigated. To clarify the mechanisms by which cell proliferation is perturbed by GEM, it is important to identify genes that show differential expression in response to GEM.
The development of cDNA microarray technology has allowed innovative studies of the levels of expression of thousands of genes with a single experiment. In the present study, we used cDNA microarray technology to investigate the mechanism that underlies the inhibition of cell proliferation by GEM in pancreatic cancer. Given the previous findings that clinical efficacy does not require cytotoxic doses of GEM (7, 8) , we focused on the effects of lower concentrations of GEM.
Materials and methods
Cell line and cell cytotoxicity. We used the YPK-1 cell line, which was established from human pancreatic cancer (15, 16) . YPK-1 cells were maintained in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal calf serum, 100 U/ml penicillin G, and 100 μg/ml streptomycin. GEM was provided by Eli Lilly Research Laboratories (Indianapolis, IN, USA). MTT (assays of YPK-1 cells were performed to evaluate the cytotoxicity of GEM as described previously (14) . The 50% inhibitory concentration (IC50) at 72 h after treatment was 6.3x10 -3 μg/ml.
Cell growth assay of GEM.
To investigate the effect of GEM on the proliferation of YPK-1 cells, we performed cell growth ONCOLOGY REPORTS 16: 1285 -1291 , 2006 Molecular features linked to the growth-inhibitory effects of gemcitabine on human pancreatic cancer cells assays. YPK-1 cells were collected by trypsinization, and 1x10 5 cells were plated in 2x10 cm dishes. The cells were allowed to attach overnight and were then exposed to one of three concentrations of GEM, 0 μg/ml (control), 3.2x10 -3 μg/ml (half IC50), and 1.6x10 -3 μg/ml (quarter IC50) for 5 days. The number of viable cells was determined by the trypan blue dye exclusion method. Experiments were performed in triplicate, and the mean values of the three experiments were calculated.
Cell cycle analysis. Cells cultured with the three different concentrations of GEM (control, half IC50, and quarter IC50) were harvested at 6, 12, 24, and 72 h after treatment. Cells were stained with propidium iodide and analyzed by laser scanning cytometry (LSC) (LSC2; Olympus Co., Tokyo, Japan) as described previously (17) .
cDNA microarray and data analysis. Differential gene expression in response to different concentrations of GEM was examined by cDNA microarray as described previously (14) . Briefly, total cellular RNA was extracted with Isogen (Nippon Gene, Tokyo, Japan) from GEM-exposed cells at 1, 6, 12, 24 , and 72 h after treatment. Cy5-dUTP-and Cy3-dUTP-(Amersham Biosciences, Piscataway, NJ, USA) labeled probes Cell cycle responses to the three concentrations of GEM were analyzed at 6, 12, 24, and 72 h after treatment. Cells exposed to quarter IC50 GEM showed a block in late S phase, and the block appeared to be reversible at 72 h. Cells exposed to half IC50 of GEM increased the number of cells in G1 phase at a relatively early time after treatment with GEM.
were synthesized from total RNA per the manufacturer's protocol. We used a commercially available cDNA microarray, Human Chip version 1.0 (DNA Chip Research, Kanagawa, Japan), which contains 2976 cDNAs. The labeled probes were mixed with a hybridization solution. After hybridization, the slides were washed five times. Slides were scanned with a GenePix 4000 scanner (Axon Instruments, Union City, CA, USA). The fluorescence intensity of spot was compared to the local background, and background subtraction was performed. To normalize the data, the fluorescence ratio for each gene was adjusted to a median ratio value of all spots in the array of 1.0. Spots for which the ratio of the backgroundsubtracted signal intensity to the local background was less than 3 were excluded from analysis. The ratios of each spot in duplicate experiments were averaged. Genes were categorized as temporal and significant profile changes if the ratio difference was 2.5-fold or greater for at least one time point, as shown in Fig. 1 . Self-organizing map (SOM) analysis was performed with DNASIS Stat (DNA Chip Research). A threerow by three-column SOM was generated with an initial learning rate of 0.5 and an initial neighborhood size of 10.
RT-PCR analysis. To validate our microarray results for the SPARC and RPS8 genes, we carried out RT-PCR of these genes with the same RNAs used for the initial screening. The reverse transcriptase step was performed as described previously (14) . Five microliters of cDNA solution (equivalent to the cDNA from 100 ng of initial RNA) was amplified in 45 μl of PCR mixture containing 25 pmol of each primer for each target gene. Each cycle consisted of denaturation at 94˚C for 1 min, annealing at 61˚C for 45 sec, and elongation at 72˚C for 2 min. PCR protocols, primer sequences, and expected product sizes are shown in Table I . PCR products were separated by electrophoresis on 2.0% agarose gels and visualized by UV irradiation after ethidium bromide staining.
Statistical analysis. All data are presented as mean ± SE. Statistical analyses were performed with repeated measures one-way analysis of variance (ANOVA) with StatView software (SAS Institute, Cary, NC, USA). Significance was defined as a p value of <0.05.
Results

Perturbation of cell proliferation by GEM.
We first investigated how distinct concentrations of GEM affect the proliferation of YPK-1 cells. The growth curves differed significantly between the two concentrations in a dose-dependent manner (p<0.0001) (Fig. 2) .
Influence of GEM on cell cycle progression. Changes in the cell cycle in response to different concentrations of GEM are shown in Fig. 3 . A DNA histogram of control cells was almost unchanged from 6 h to 72 h after exposure of cells to GEM. Exposure of cells to quarter IC50 caused an accumulation of cells in the S phase between 12 and 24 h after exposure. This DNA histogram pattern had returned to normal by 72 h after exposure. In contrast, exposure of cells to half IC50 increased the number of cells in the G1 phase at 6 h after GEM exposure, and this was accompanied by a small sub-G1 peak at 72 h and appeared to lead into apoptosis.
Gene expression analysis by SOM in YPK-1 cells exposed to GEM. Genes were subjected to cluster analysis and a ninepartition SOM with a 3x3 algorithm (Fig. 4 , Tables II and III) . The resulting clusters were independent of the biological functions of the selected genes. The analysis revealed temporal changes in the expression of genes related to the cell cycle, transporter or immune response. The genes appeared to reflect the cellular response to GEM. We identified 24 genes whose expression altered in response to two different concentrations of GEM. The expression level of most genes was unchanged in cells exposed to either half IC50 or quarter IC50 of GEM for 24 h.
Validation of microarray data by RT-PCR.
To validate the microarray data, we carried out RT-PCR of SPARC and RPS8, two genes selected randomly from the genes showing differential expression in response to GEM. The temporal changes in expression of the genes were consistent with the corresponding SOM patterns (Fig. 5) . Thus, the microarray data were validated by the RT-PCR results.
Discussion
GEM blocks cell cycle progression in cells at the appropriate concentration (18) . In the present study, G1 arrest was observed in cells exposed to half IC50 of GEM, and subG1 was observed in cells exposed to GEM for 72 h. It was anticipated that cells with suppressed proliferation would undergo apoptosis after 72 h (day 3). These observations were consistent with the findings of our growth assay (Fig. 1) . ONCOLOGY REPORTS 16: 1285 -1291 , 2006 Table I. Primers of RPS8, SPARC, and GAPDH. ------------------------------------------------------------------------------------------------- ----Cells exposed to quarter IC50 of GEM temporarily accumulated in late S phase, indicating that progression through S phase might be delayed. At 72 h of exposure, there was no significant difference between the quarter IC50 and the control. Thus, a low concentration of GEM prolongs the S phase of YPK-1 cells. It is intriguing to investigate a set of genes linked with a difference in the cellular response to GEM. Thus, it is important to focus on the change of gene expression caused by different GEM concentrations.
-----------------------------------------------------------------------------------------------------Gene symbol Primer sequence Number of PCR cycle Product size (bp) -----------------------------------------------------------------------------------------------------
Genes relevant to cell cycle regulation were identified by generation of SOMs for data from cells treated with GEM. In half IC50-treated cells, CDKN1B, a cyclin-dependent kinase inhibitor implicated in the transition from proliferation to a quiescent state (19, 20) , was classified to cluster 2, and the Table II . Temporal changed genes in half IC50. 
Gene symbols are common in quarter IC50.
- ---------------------------------------------------------------------------------------------------- expression level slowly increased until 12 h after GEM exposure. Elevated expression of CDKN1B may cause G1 arrest of cells. Although other genes showed changes in expression levels in the present study, the roles of these genes in the anti-proliferative activity of GEM remain to be clarified.
Genes encoding transporters or proteins involved in immune responses showed altered expression more frequently in cells exposed to half IC50 than in cells exposed to quarter IC50. GPX4 encodes glutathione peroxidase 4, which protects cells against oxidative damage by anti-cancer drugs (21, 22) . ATP1A1 encodes an Na + /K + transporter and is associated with the accumulation of drugs such as anti-cancer agents (23) . The expression of ABCB1, an ABC transporter that influences sensitivity to anti-cancer agents (24) , was temporarily decreased in cells exposed to quarter IC50. In contrast, the expression of genes encoding ribosome-related proteins was altered more frequently in cells exposed to quarter IC50 than in cells exposed to half IC50. The present data suggest that the expression of ribosomal proteins is linked to the susceptibility of tumor cells to chemotherapy (14, 25, 26) . However, cellular responsiveness to a drug is dependent on the concentration of the drug because different genes are affected by different concentrations of drugs.
In the present study, 24 genes showed altered expression in response to both concentrations of GEM. In most of them, gene expression patterns in hierarchical cluster analysis were not affected by GEM concentrations (data not shown). It is likely that the changes in expression are not related to the inhibitory effects of GEM on cell proliferation. However, the level of expression of 2 of the 24 genes was dependent on the concentration of GEM. Temporal changes in the expression of these genes, SPARC (cluster 8 in half IC50 and cluster 8 in quarter IC50) and YWHAZ (cluster 9 in half IC50 and cluster 4 in quarter IC50), may be regulated by different molecular pathways that respond to varying concentrations of GEM. We believe that genes showing dose-dependent responses to GEM are associated with cell proliferation.
In conclusion, the gene expression profiles from cDNA microarray analysis coupled with SOM analysis revealed the molecular responses of YPK-1 cells to different concentrations of GEM. Identification of GEM-responsive genes provides insights into the anti-cancer mechanism of GEM and has the potential for clinical use to predict cellular responses to GEM. Further studies are needed to confirm that the genes identified in the present study are associated with growth inhibition in response to GEM.
